Key Developments: Hikma Pharmaceuticals PLC (HKMPF.PK)

HKMPF.PK on OTC Markets Group - US Other OTC and Grey Market

37.20USD
10:53am EDT
Change (% chg)

$7.30 (+24.33%)
Prev Close
$29.92
Open
$37.20
Day's High
$37.20
Day's Low
$37.20
Volume
600
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Latest Key Developments (Source: Significant Developments)

Hikma Pharmaceuticals Plc announces acquisition of Roxane Laboratories Inc and Boehringer Ingelheim Roxane Inc
Tuesday, 28 Jul 2015 02:02am EDT 

Hikma Pharmaceuticals Plc:Says it has agreed to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. (together 'Roxane'), from Boehringer Ingelheim.Says Roxane is a US specialty generics company with a differentiated product portfolio and R&D capabilities.Says under the terms of the acquisition, on closing of the transaction Hikma will pay gross consideration of $1.18 billion in cash and will issue 40 million new Hikma shares to Boehringer (representing about 16.71 pct of Hikma's issued share capital immediately following closing and admission).  Full Article

Hikma Pharmaceutical reaffirms FY 2015 revenue guidance; comments on H1 2015 guidance
Thursday, 14 May 2015 02:01am EDT 

Hikma Pharmaceutical:Continue to expect FY 2015 group revenue growth of around 6 pct. in constant currency.Says on a reported basis, it expects FY 2015 group revenue growth of around 2 pct.Sees H1 2015 group revenue in constant currency to be broadly in line with the same period last year.  Full Article

Hikma Pharmaceutical launches caffeine citrate injection
Tuesday, 12 May 2015 04:00am EDT 

Hikma Pharmaceutical:Says it has launched CAFCIT Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL).CAFCIT is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.  Full Article

Hikma Pharmaceutical prices debut $500 million five-year eurobond
Wednesday, 1 Apr 2015 12:13pm EDT 

Hikma Pharmaceutical:Prices a Reg S $500 million 4.25 pct eurobond due April 2020.Proceeds will be used to refinance existing debt and for general corporate purposes.Bond will be listed on the Global Exchange Market of the Irish Stock Exchange.FCA/ICMA stabilisation applies.Says joint lead managers were Citi (Global Coordinator), Barclays, HSBC and National Bank of Abu Dhabi.  Full Article

Hikma Pharmaceuticals PLC gives FY 2015 revenue guidance in line with analysts' estimates
Wednesday, 11 Mar 2015 03:01am EDT 

Hikma Pharmaceuticals PLC:Expects FY 2015 Group revenue growth of around 6 pct in constant currency.Reported revenue of $1.489 bln in FY 2014.FY 2015 revenue of $1.609 bln - Thomson Reuters I/B/E/S.  Full Article

Hikma Pharmaceuticals PLC recommends dividends
Wednesday, 11 Mar 2015 03:01am EDT 

Hikma Pharmaceuticals PLC:Proposes final dividend of 15.0 cents per share, plus a special dividend of 6.0 cents per share.Proposed final dividend and final special dividend will be paid on May 21, 2015 to eligible shareholders on the register of Hikma at the close of business on April 17.  Full Article

Hikma Pharmaceuticals PLC raises FY 2014 revenue guidance
Thursday, 6 Nov 2014 02:01am EST 

Hikma Pharmaceuticals PLC:Says that it is raise it's guidance for FY 2014 to Group revenue growth of around 7 pct.Reported revenue of $1.365 bln in FY 2013.  Full Article

Hikma Pharmaceuticals PLC announces receipt of warning letter from FDA
Friday, 24 Oct 2014 02:00am EDT 

Hikma Pharmaceuticals PLC:Says it received warning letter from U.S. FDA on 23 Oct. 23.Says letter related to inspection of its manufacturing facility in Portugal in March 2014.In letter, agency raised issues related to investigations and environmental monitoring at facility.Hikma takes this matter very seriously and will work with FDA to fully resolve all outstanding issues.  Full Article

Hikma completes acquisition of Ben Venue manufacturing site
Wednesday, 17 Sep 2014 02:01am EDT 

Hikma Pharmaceuticals Plc:Says that it has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, Inc, part of the Boehringer Ingelheim Group of Companies, as agreed on July 24.Says the Ben Venue site includes four manufacturing plants and a state-of-the-art Quality and Development Centre.  Full Article

Hikma Pharmaceutical Plc declares dividend
Wednesday, 20 Aug 2014 11:00am EDT 

Hikma Pharmaceutical Plc:As previously announced with interim results, company is paying total dividend of 11 cents per share, comprising interim dividend of 7.0 cents and special dividend of 4 cents.Interim and special dividend will be paid on Sept. 26, 2014 to eligible shareholders on register at close of business on Aug. 29, 2014.Ex-dividend date is Aug. 27, 2014 and final date for currency elections is Sept. 12, 2014.  Full Article

Search Stocks